Extract
A phase III trial of delamanid showed acceptable safety and tolerability; however, it failed to demonstrate superior efficacy of delamanid in terms of reduction in time to sputum conversion and improvement in final treatment outcomes compared with placebo [1]. How to interpret these results and identify the role of delamanid in multidrug-resistant tuberculosis (MDR-TB) treatment is challenging [2]. Despite the disappointing results, this trial suggests that more studies are needed to better understand the role of delamanid in the current management of MDR-TB. So far, there have been several reports of real-world data on the interim outcomes of delamanid treatment [3–6], but few on its final outcomes [7].
Abstract
The optimised use of delamanid combined with effective repurposed drugs could achieve a high treatment success rate, even in pre-extensively drug-resistant (XDR)-TB and XDR-TB patients http://bit.ly/2plvEOT
Footnotes
Conflict of interest: J. Mok has nothing to disclose.
Conflict of interest: H. Kang has nothing to disclose.
Conflict of interest: W-J. Koh has nothing to disclose.
Conflict of interest: B.W. Jhun has nothing to disclose.
Conflict of interest: J-J. Yim has nothing to disclose.
Conflict of interest: N. Kwak has nothing to disclose.
Conflict of interest: T. Lee has nothing to disclose.
Conflict of interest: B. Kang has nothing to disclose.
Conflict of interest: D. Jeon has nothing to disclose.
- Received April 23, 2019.
- Accepted June 30, 2019.
- Copyright ©ERS 2019
INDIVIDUALS
Log in using your username and password
LIBRARY USERS
Log in through your institution
Purchase access
CONTACT US
If you have any questions about the ERS publications website, please contact journals@ersnet.org
